Results 311 to 320 of about 3,108,169 (356)

Vaccines against advanced melanoma

Clinics in Dermatology, 2013
Research shows that cancers are recognized by the immune system but that the immune recognition of tumors does not uniformly result in tumor rejection or regression. Quantitating the success or failure of the immune system in tumor elimination is difficult because we do not really know the total numbers of encounters of the immune system with the ...
Tatiana, Blanchard, Pramod K, Srivastava, Fei, Duan   +2 more
openaire   +2 more sources

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

The Lancet Oncology, 2018
BACKGROUND Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and overall survival with nivolumab plus ipilimumab or nivolumab alone compared with ...
F. Hodi, V. Chiarion-Sileni, R. Gonzalez, J. Grob, P. Rutkowski, C. Cowey, C. Lao, D. Schadendorf, J. Wagstaff, R. Dummer, P. Ferrucci, M. Smylie, A. Hill, D. Hogg, I. Márquez-Rodas, Joel Jiang, J. Rizzo, J. Larkin, J. Wolchok   +18 more
semanticscholar   +1 more source

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

New England Journal of Medicine
Background The phase 3 CheckMate 067 trial has demonstrated improved survival with nivolumab-plus-ipilimumab or nivolumab monotherapy compared with ipilimumab monotherapy in patients with advanced melanoma. Here, we report the final, 10-year results from
J. Wolchok, V. Chiarion-Sileni, Piotr Rutkowski, C. Cowey, D. Schadendorf, John Wagstaff, P. Queirolo, R. Dummer, Marcus O. Butler, A. Hill, Michael A. Postow, C. Gaudy-Marqueste, Theresa Medina, Christopher D. Lao, J. Walker, I. Márquez-Rodas, John B. A G. Haanen, M. Guidoboni, Michele Maio, P. Schöffski, M. Carlino, S. Sandhu, Céleste Lebbé, P. Ascierto, Georgina V. Long, C. Ritchings, A. Nassar, M. Askelson, M. Benito, Wenjia Wang, F. Hodi, J. Larkin   +31 more
semanticscholar   +1 more source

Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.

Annals of Oncology
BACKGROUND Pembrolizumab significantly improved overall survival (OS) versus ipilimumab for unresectable advanced melanoma in KEYNOTE-006 (NCT01866319); 10-year follow-up data are presented.
G. V. Long, M. Carlino, C. McNeil, A. Ribas, C. Gaudy-Marqueste, J. Schachter, M. Nyakas, D. Kee, T. Petrella, A. Blaustein, M. Lotem, A. Arance, A. Daud, O. Hamid, J. Larkin, L. Yao, R. Singh, R. Lal, C. Robert   +18 more
semanticscholar   +1 more source

Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.

The Lancet Oncology, 2021
BACKGROUND The dependence of the adaptive immune system on circadian rhythm is an emerging field of study with potential therapeutic implications. We aimed to determine whether specific time-of-day patterns of immune checkpoint inhibitor infusions might ...
D. Qian, T. Kleber, B. Brammer, Karen M. Xu, J. Switchenko, J. Janopaul-Naylor, J. Zhong, M. Yushak, R. Harvey, C. Paulos, D. Lawson, Mohammad K. Khan, R. Kudchadkar, Z. Buchwald   +13 more
semanticscholar   +1 more source

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).

, 2021
9503Background: Immune checkpoint inhibitor therapy has revolutionized the treatment of patients with advanced melanoma.
E. Lipson, H. Tawbi, D. Schadendorf, P. Ascierto, L. Matamala, E. C. Gutiérrez, P. Rutkowski, H. Gogas, C. Lao, J. Menezes, S. Dalle, A. Arance, J. Grob, Shivani Srivastava, Mena Abaskharoun, K. Simonsen, Bin Li, G. Long, F. Hodi   +18 more
semanticscholar   +1 more source

Research progress in advanced melanoma

Cancer Letters, 2017
Melanoma is a malignant tumor with high rate of metastasis and poor prognosis. How melanoma develops and how to treat it will continue to be a hot topic. This review briefly summarizes the mechanism of melanoma development and the latest progress in its treatment.
Cong, Luo, Jiayu, Shen
openaire   +2 more sources

Chemotherapy for advanced malignant melanoma

International Journal of Clinical & Laboratory Research, 1992
Systemic chemotherapy for the treatment of metastatic melanoma remains disappointing. Nor new single agent has demonstrated promising results. The combination of cisplatin, decarbazine, carmustine, and tamoxifen appears to be one of the most active regimens with an overall response rate approaching 50%. In some patients, responses have been durable and
A C, Buzaid, J, Murren
openaire   +2 more sources

CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.

, 2021
9506 Background: In the phase 3 CheckMate 067 trial, a durable and sustained clinical benefit was achieved with nivolumab (NIVO) + ipilimumab (IPI) and NIVO alone vs IPI at 5-y of follow-up (overall survival [OS] and progression-free survival [PFS] rates:
J. Wolchok, V. Chiarion-Sileni, R. Gonzalez, J. Grob, P. Rutkowski, C. Lao, C. Cowey, D. Schadendorf, J. Wagstaff, R. Dummer, P. Ferrucci, M. Smylie, M. Butler, A. Hill, I. Márquez-Rodas, J. Haanen, T. Bas, Wim van Dijck, J. Larkin, F. Hodi   +19 more
semanticscholar   +1 more source

Adoptive Immunotherapy of Advanced Melanoma

Current Treatment Options in Oncology, 2012
Adoptive cell therapy (ACT) has emerged as an effective therapy for patients with metastatic melanoma. Since the first introduction of the protocol in 1988 [1], major improvements have been achieved with response rates of 40%-72% among patients who were resistant to previous treatment lines.
Ronnie, Shapira-Frommer, Jacob, Schachter   +1 more
openaire   +2 more sources